Abstract | OBJECTIVE: DATA SOURCES: Literature retrieval was accessed through MEDLINE (1966-March 2011), Cochrane Library, and EMBASE, using the terms dapsone and methemoglobinemia. STUDY SELECTION AND DATA EXTRACTION: All case reports, small case series, and randomized controlled trials published in English were evaluated. Because of the absence of comprehensive updates on this topic since 1996, publications between 1997 and March 2011 were included in this review. DATA SYNTHESIS: CONCLUSIONS: Clinicians should recognize methemoglobinemia as an adverse effect associated with dapsone use and the potential factors that precipitate it. They should also know how to promptly and effectively manage this event.
|
Authors | James A Barclay, Stamatina E Ziemba, Rami B Ibrahim |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 45
Issue 9
Pg. 1103-15
(Sep 2011)
ISSN: 1542-6270 [Electronic] United States |
PMID | 21852596
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Infective Agents
- Enzyme Inhibitors
- Dapsone
- Methylene Blue
|
Topics |
- Anemia, Hemolytic
(etiology)
- Anti-Infective Agents
(adverse effects)
- Dapsone
(adverse effects)
- Enzyme Inhibitors
(therapeutic use)
- Humans
- Methemoglobinemia
(chemically induced, drug therapy, physiopathology)
- Methylene Blue
(therapeutic use)
- Risk Factors
- Treatment Outcome
|